Cargando…
Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs
PURPOSE: The present study aimed to evaluate the incidence rate of radiation pneumonitis (RP) in patients with advanced lung adenocarcinoma treated with first-generation (1G), second-generation (2G), or third-generation (3G) epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) com...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106805/ https://www.ncbi.nlm.nih.gov/pubmed/37077536 http://dx.doi.org/10.2147/CMAR.S404874 |
_version_ | 1785026487518232576 |
---|---|
author | Mu, Fengchun Fan, Bingjie Li, Butuo Qin, Wenru Li, Haoqian Wang, Chunni Zou, Bing Wang, Shijiang Wang, Linlin |
author_facet | Mu, Fengchun Fan, Bingjie Li, Butuo Qin, Wenru Li, Haoqian Wang, Chunni Zou, Bing Wang, Shijiang Wang, Linlin |
author_sort | Mu, Fengchun |
collection | PubMed |
description | PURPOSE: The present study aimed to evaluate the incidence rate of radiation pneumonitis (RP) in patients with advanced lung adenocarcinoma treated with first-generation (1G), second-generation (2G), or third-generation (3G) epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with thoracic radiotherapy (TRT). PATIENTS AND METHODS: Patients with advanced lung adenocarcinoma simultaneously treated with 1G/2G/3G EGFR-TKIs and TRT between 2015–2021 at Shandong Cancer Hospital and Institute were screened. The incidence rate of clinical and imaging RP was compared between the three groups. RESULTS: A total of 200 patients treated with EGFR-TKIs were enrolled in this study, including 100 patients who were treated with 1G EGFR-TKIs, 50 patients who were treated with 2G EGFR-TKIs, and 50 patients who were treated with 3G EGFR-TKIs (patients matched in a 2:1:1 ratio for tumor characteristics). The overall incidence of clinical RP in the 1G, 2G, and 3G EGFR-TKI groups were 29%, 48%, and 28% (p=0.043), respectively, and that of imaging RP were 33%, 58%, and 36% (p=0.010), respectively. The incidence of RP with a clinical grade ≥3 in the three groups were 14%, 28%, and 12% (p=0.055), respectively, and that with an imaging grade ≥3 in the three groups were 11%, 32%, and 10% (p=0.002), respectively. The incidence of clinical RP was higher in the CFRT group than in the SBRT group, with an overall clinical grade of 38% vs 10% (p<0.001) and imaging grade of 46% vs 10% (p<0.001), respectively. In the multivariate analysis, only GTV volume was an independent predictive factor for all risks of clinical and imaging RP. V20 and grouping of 1G/2G/3G EGFR-TKIs were other independent predictive factors for the risk factors of RP for imaging grades. CONCLUSION: Compared with 2G EGFR-TKIs combined with TRT, 1G or 3G EGFR-TKIs combined with TRT achieved a lower incidence of RP. |
format | Online Article Text |
id | pubmed-10106805 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-101068052023-04-18 Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs Mu, Fengchun Fan, Bingjie Li, Butuo Qin, Wenru Li, Haoqian Wang, Chunni Zou, Bing Wang, Shijiang Wang, Linlin Cancer Manag Res Original Research PURPOSE: The present study aimed to evaluate the incidence rate of radiation pneumonitis (RP) in patients with advanced lung adenocarcinoma treated with first-generation (1G), second-generation (2G), or third-generation (3G) epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with thoracic radiotherapy (TRT). PATIENTS AND METHODS: Patients with advanced lung adenocarcinoma simultaneously treated with 1G/2G/3G EGFR-TKIs and TRT between 2015–2021 at Shandong Cancer Hospital and Institute were screened. The incidence rate of clinical and imaging RP was compared between the three groups. RESULTS: A total of 200 patients treated with EGFR-TKIs were enrolled in this study, including 100 patients who were treated with 1G EGFR-TKIs, 50 patients who were treated with 2G EGFR-TKIs, and 50 patients who were treated with 3G EGFR-TKIs (patients matched in a 2:1:1 ratio for tumor characteristics). The overall incidence of clinical RP in the 1G, 2G, and 3G EGFR-TKI groups were 29%, 48%, and 28% (p=0.043), respectively, and that of imaging RP were 33%, 58%, and 36% (p=0.010), respectively. The incidence of RP with a clinical grade ≥3 in the three groups were 14%, 28%, and 12% (p=0.055), respectively, and that with an imaging grade ≥3 in the three groups were 11%, 32%, and 10% (p=0.002), respectively. The incidence of clinical RP was higher in the CFRT group than in the SBRT group, with an overall clinical grade of 38% vs 10% (p<0.001) and imaging grade of 46% vs 10% (p<0.001), respectively. In the multivariate analysis, only GTV volume was an independent predictive factor for all risks of clinical and imaging RP. V20 and grouping of 1G/2G/3G EGFR-TKIs were other independent predictive factors for the risk factors of RP for imaging grades. CONCLUSION: Compared with 2G EGFR-TKIs combined with TRT, 1G or 3G EGFR-TKIs combined with TRT achieved a lower incidence of RP. Dove 2023-04-12 /pmc/articles/PMC10106805/ /pubmed/37077536 http://dx.doi.org/10.2147/CMAR.S404874 Text en © 2023 Mu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Mu, Fengchun Fan, Bingjie Li, Butuo Qin, Wenru Li, Haoqian Wang, Chunni Zou, Bing Wang, Shijiang Wang, Linlin Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs |
title | Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs |
title_full | Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs |
title_fullStr | Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs |
title_full_unstemmed | Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs |
title_short | Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs |
title_sort | comparison of the incidence rate of radiation pneumonitis observed in patients with advanced lung adenocarcinoma treated with simultaneous thoracic radiotherapy and 1g/2g/3g egfr-tkis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106805/ https://www.ncbi.nlm.nih.gov/pubmed/37077536 http://dx.doi.org/10.2147/CMAR.S404874 |
work_keys_str_mv | AT mufengchun comparisonoftheincidencerateofradiationpneumonitisobservedinpatientswithadvancedlungadenocarcinomatreatedwithsimultaneousthoracicradiotherapyand1g2g3gegfrtkis AT fanbingjie comparisonoftheincidencerateofradiationpneumonitisobservedinpatientswithadvancedlungadenocarcinomatreatedwithsimultaneousthoracicradiotherapyand1g2g3gegfrtkis AT libutuo comparisonoftheincidencerateofradiationpneumonitisobservedinpatientswithadvancedlungadenocarcinomatreatedwithsimultaneousthoracicradiotherapyand1g2g3gegfrtkis AT qinwenru comparisonoftheincidencerateofradiationpneumonitisobservedinpatientswithadvancedlungadenocarcinomatreatedwithsimultaneousthoracicradiotherapyand1g2g3gegfrtkis AT lihaoqian comparisonoftheincidencerateofradiationpneumonitisobservedinpatientswithadvancedlungadenocarcinomatreatedwithsimultaneousthoracicradiotherapyand1g2g3gegfrtkis AT wangchunni comparisonoftheincidencerateofradiationpneumonitisobservedinpatientswithadvancedlungadenocarcinomatreatedwithsimultaneousthoracicradiotherapyand1g2g3gegfrtkis AT zoubing comparisonoftheincidencerateofradiationpneumonitisobservedinpatientswithadvancedlungadenocarcinomatreatedwithsimultaneousthoracicradiotherapyand1g2g3gegfrtkis AT wangshijiang comparisonoftheincidencerateofradiationpneumonitisobservedinpatientswithadvancedlungadenocarcinomatreatedwithsimultaneousthoracicradiotherapyand1g2g3gegfrtkis AT wanglinlin comparisonoftheincidencerateofradiationpneumonitisobservedinpatientswithadvancedlungadenocarcinomatreatedwithsimultaneousthoracicradiotherapyand1g2g3gegfrtkis |